Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Personalized Medicine: Recent Progress in Cancer Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 29 February 2020.
Interests: palliative care; cancer pain; opioids; NMDA; symptoms in cancer
Interests: neuro-oncology; palliative care; personolised medicine
Interests: neuropathic pain; NMDA; opioids; cancer pain; spinal cord; nociception; mechanism of action; pharmacology of pain
Personalized medicine (PM) or precision medicine in oncology is an emerging approach for tumor treatment and prevention, which takes into account inter- and intra-tumoral variability in genes, tumor (immune) environment, and lifestyle and morbidities of each person diagnosed with cancer. PM has the potential to tailor therapy towards the oncogenic drivers of the tumor and modulate the tumor immune environment, not only attempting to optimize tumor response, but also taking into account therapy-induced toxicities for each specific patient. In this way, optimized tumor response is combined with the preservation of organ function and quality of life, ensuring better patient care.
Biomarker development is a rapidly evolving field in PM and makes it possible to not only predict prognosis, but also to predict treatment response. Predictive biomarker models are not only defined by serum markers, but also by different imaging modalities (CT, MR, nuclear imaging modalities), creating multimodal (non-invasive) predictive platforms identifying the molecular fingerprint of the tumor.
Finetuning of predictive models will enable the construction of tumor-tailored treatment plans and improve prognostic models, which will facilitate shared decision-making, allowing for a patient-tailored treatment plan.
By enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments, PM holds promise for improving health care while also lowering costs.
This Special Issue will highlight recent advances in personalized medicine in treating cancer and its accompanying symptoms.
Prof. Dr. Marieke H.J. van den Beuken-van Everdingen
Dr. Ann Hoeben
Prof. Dr. Elbert A.J. Joosten
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- personalized medicine